Mölnlycke Health Care and Zhende Medical announced the formation of a new joint venture company in China to expand access to advanced wound care solutions in one of the world’s fastest-growing wound care markets.
The joint venture, majority-owned by Mölnlycke, will integrate both companies’ wound care portfolios and commercial capabilities to provide healthcare providers and patients across China with broader access to advanced treatments, improved care delivery, and better patient outcomes.
The collaboration combines Mölnlycke’s advanced wound care portfolio, including its Safetac® technology and Mepiform® scar care dressing, with Zhende Medical’s wound care products and nationwide distribution network spanning nearly 10,000 hospitals, 200,000 pharmacies, and eCommerce channels across China.
China’s advanced wound dressing market is valued at approximately EUR 380 million (RMB 3 billion), driven by rising chronic disease prevalence, an ageing population, and increasing demand for advanced treatment solutions.
Click here to join our WhatsApp channel here
The joint venture, named Mölnlycke Zhende (Shanghai) Medical Technology Co Ltd, will operate as a standalone entity headquartered in Shanghai and is expected to become operational in Q3 2026.
Guillaume Joucla, Interim CEO of Mölnlycke Health Care, said: “This joint venture represents an important milestone in the growth journey of both Mölnlycke and Zhende Medical. By joining forces, we are strengthening our presence in China, expanding our wound care portfolio and significantly enhancing our go-to-market capabilities to better serve more customers and patients.”
Dasheng Xu, Board Director and Executive President of Zhende Medical, added: “This partnership demonstrates the strength, resilience and long-term ambition of both companies. By combining our complementary capabilities and deep market knowledge, we are well positioned to meet the growing demand for advanced wound care solutions in China.”
